REPL
Price
$13.09
Change
-$0.36 (-2.68%)
Updated
Oct 2, 04:59 PM (EDT)
Capitalization
1.18B
27 days until earnings call
Intraday BUY SELL Signals
SNDX
Price
$17.61
Change
-$0.61 (-3.35%)
Updated
Oct 2, 04:59 PM (EDT)
Capitalization
1.59B
27 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

REPL vs SNDX

REPL vs SNDX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
REPL vs. SNDX commentary
Oct 02, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is REPL is a Buy and SNDX is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
REPL vs SNDX: Fundamental Ratings
REPL
SNDX
OUTLOOK RATING
1..100
1513
VALUATION
overvalued / fair valued / undervalued
1..100
54
Fair valued
95
Overvalued
PROFIT vs RISK RATING
1..100
10099
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
3659
P/E GROWTH RATING
1..100
1004
SEASONALITY SCORE
1..100
7550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

REPL's Valuation (54) in the Biotechnology industry is somewhat better than the same rating for SNDX (95). This means that REPL’s stock grew somewhat faster than SNDX’s over the last 12 months.

SNDX's Profit vs Risk Rating (99) in the Biotechnology industry is in the same range as REPL (100). This means that SNDX’s stock grew similarly to REPL’s over the last 12 months.

REPL's SMR Rating (99) in the Biotechnology industry is in the same range as SNDX (100). This means that REPL’s stock grew similarly to SNDX’s over the last 12 months.

REPL's Price Growth Rating (36) in the Biotechnology industry is in the same range as SNDX (59). This means that REPL’s stock grew similarly to SNDX’s over the last 12 months.

SNDX's P/E Growth Rating (4) in the Biotechnology industry is significantly better than the same rating for REPL (100). This means that SNDX’s stock grew significantly faster than REPL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
REPLSNDX
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
86%
MACD
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 3 days ago
81%
Declines
ODDS (%)
Bearish Trend 8 days ago
83%
Bearish Trend 17 days ago
77%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
69%
COMPARISON
Comparison
Oct 02, 2026
Stock price -- (REPL: $13.45 vs. SNDX: $18.22)
Brand notoriety: REPL and SNDX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: REPL: 43% vs. SNDX: 94%
Market capitalization -- REPL: $1.18B vs. SNDX: $1.59B
REPL [@Biotechnology] is valued at $1.18B. SNDX’s [@Biotechnology] market capitalization is $1.59B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

REPL’s FA Score shows that 0 FA rating(s) are green while SNDX’s FA Score has 1 green FA rating(s).

  • REPL’s FA Score: 0 green, 5 red.
  • SNDX’s FA Score: 1 green, 4 red.
According to our system of comparison, both REPL and SNDX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

REPL’s TA Score shows that 4 TA indicator(s) are bullish while SNDX’s TA Score has 5 bullish TA indicator(s).

  • REPL’s TA Score: 4 bullish, 5 bearish.
  • SNDX’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, SNDX is a better buy in the short-term than REPL.

Price Growth

REPL (@Biotechnology) experienced а +6.75% price change this week, while SNDX (@Biotechnology) price change was +1.39% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.98%. For the same industry, the average monthly price growth was -14.69%, and the average quarterly price growth was -2.11%.

Reported Earning Dates

REPL is expected to report earnings on Oct 29, 2026.

SNDX is expected to report earnings on Oct 29, 2026.

Industries' Descriptions

@Biotechnology (-3.98% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
REPL
Daily Signal:
Gain/Loss:
SNDX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AX87.611.04
+1.20%
Axos Financial
THRM33.630.33
+0.99%
Gentherm
ORLY85.03-0.38
-0.44%
O'Reilly Automotive Inc
AIRO6.54-0.07
-1.06%
AIRO Group Holdings Inc.
DSY3.51-0.15
-4.10%
Big Tree Cloud Holdings Limited

REPL and

Correlation & Price change

A.I.dvisor indicates that over the last year, REPL has been loosely correlated with IMNN. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if REPL jumps, then IMNN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REPL
1D Price
Change %
REPL100%
+1.59%
IMNN - REPL
57%
Loosely correlated
+2.33%
SNDX - REPL
49%
Loosely correlated
-3.09%
KYMR - REPL
45%
Loosely correlated
-1.49%
NRIX - REPL
43%
Loosely correlated
-1.56%
ZYME - REPL
42%
Loosely correlated
-2.00%
More